The Centers for Disease Control and Prevention (CDC) measures the amounts of just 300 chemicals in only 2,500 persons every two years. Those studies show that many of those chemicals are within our bodies at high levels. Those CDC processes are very costly and not available to everyday people. XCellAssay has created an affordable technology that uses cell lines engineered to alert you which chemical types are in your bodies at levels that may affect your health. XCellAssay also seeks to compare your measurements with the experiences and measurements of millions of other users, to provide recommendations to reverse any chemical disruption of your health.
Fred Schaufele, PhD
Managing Partner and Director of Scientific Operations
Irina Krylova, PhD
Director of Environmental Studies
HaiGuang Zhang, PhD
Director of Technology
Director of Digital Technology
The COVID-19 response has required the cancellation of the annual meeting of The Endocrine Society, at which Dr. Schaufele and Dr. Krylova had been scheduled to present XCellAssay studies. The Endocrine Society currently is considering alternative mechanisms to present “Advantages and Limitations of an Integrative Measurement for All Serum Androgens and Anti-Androgens” (from Dr. Schaufele and UCSF collaborators Dr. Armaiti and Dr. Huddleston) and “Dynamic Structural Model of Testosterone Entry into the Unliganded Androgen Receptor” (from Drs. Krylova, Schaufele and Guilbert).
XCellAssay announces the continuation of funding by the Partnership for Clean Competition (PCC) for the development of our technology for identifying persons exposed to known or unknown androgens or anabolic androgenic steroids. The PCC, which was founded by the U.S. Olympic & Paralympic Committee, the US Anti-Doping Agency, the National Football League and Major League Baseball, has awarded three research studies by Dr. Schaufele to develop the measurement capability as part of the PCC’s mission “to help generate the world’s most influential, effective and coveted methods and resources for detecting and deterring the use of performance enhancing substances by all athletes in all sports at all levels”.
Dr. Schaufele and his UCSF collaborators Drs. Armaiti and Huddleston will present the abstract “Advantages and Limitations of an Integrative Measurement for All Serum Androgens and Anti-Androgens” at the 2020 annual meeting of The Endocrine Society. The paper will describe the supporting data validating the androgen measurement technique for serum samples and its applications for detecting elevated androgen levels in patients with a PCOS diagnosis compared to women not meeting formal PCOS criteria.
XCellAssay announces renewal of its agreement for the right to negotiate an exclusive license with the UCSF Office of Innovation Ventures for the technology covered in US Patent #10,324,099 (Inventor, Dr. Fred Schaufele, co-Founder, XCellAssay). A prior freedom to operate analysis conducted with the Startup Legal Garage program of the University of California Hastings College of the Law indicated that no patents or patent applications were found at the time of the report that “appear to have issued claims or claims that are likely to issue that should be infringed by the XCA’s Product”.
XCellAssay is located in the MBC BioLabs incubator (formerly QB3@953) beside the University of California San Francisco’s Mission Bay campus